RespireRx Pharmaceuticals Inc (fka RSPI)

[ombowstring]

gfp, I don't know why you're hinting that there might be a problem with CX1739 or CX1846. Conversely, if Samyang ran clinical trials and the data showed efficacy, that would be a plus for Cortex in negotiations with other potential partners (although the results of a trial run by Samyang would be probably at least a year away and thus this might be a moot point). we don't want to shy away from clinical trials; we want them to take place. AMPAKINES are showing reasonably good results in all trials so far so the more trials that are run, the better Cortex should look. I just don't see what you're suggesting as a big problem. And it may never eventuate.

Cortex has to come up with something bigger than this development anyway, and soon.